Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

10.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.3K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

3.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Mismatch Repair01:20

Mismatch Repair

6.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.8K
Mismatch Repair01:36

Mismatch Repair

44.1K
Overview
44.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glycosphingolipids regulate phosphatidylserine transport machinery that operates at ER-PM contact sites.

Nature communications·2026
Same author

Bipartite DNA binding domain of transcription factor BCL11B binds clustered short DNA sequence motifs.

bioRxiv : the preprint server for biology·2026
Same author

AI-Guided <i>De Novo</i> Design of a Caffeine-Induced Protein Dissociation System.

Journal of the American Chemical Society·2026
Same author

Genetically Encoded Tools to Monitor and Interrogate Membrane Contact Sites.

Contact (Thousand Oaks (Ventura County, Calif.))·2026
Same author

Phage Display Driven Identification and Computational Mapping of Macrocyclic Peptides Targeting RhoA G17V.

Biochemistry·2026
Same author

Engineering of genetically encoded programmable calcium channel inhibitory binders.

Nature communications·2026

Related Experiment Video

Updated: Mar 3, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

Early Driver, Late Bystander: Stage-Specific Roles of DNMT3A R882 Mutations Unveiled in Human AML.

Yubin Zhou1,2, Yun Huang1,2

  • 1Institute of Biosciences and Technology, Texas A&M University, Houston, Texas.

Cancer Discovery
|March 2, 2026
PubMed
Summary

DNA methyltransferase 3A (DNMT3A) R882 mutations are crucial for early leukemia development, sustaining self-renewal and inflammation. However, these mutations become less critical once acute myeloid leukemia is established, suggesting early therapeutic intervention.

More Related Videos

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

8.7K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.9K

Related Experiment Videos

Last Updated: Mar 3, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

8.7K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.9K

Area of Science:

  • Hematology
  • Molecular Biology
  • Cancer Research

Background:

  • Mutations in DNA methyltransferase 3A (DNMT3A) are common in acute myeloid leukemia (AML).
  • The arginine 882 (R882) mutation in DNMT3A is frequently observed and linked to poor prognosis.
  • The precise role of DNMT3A R882 mutations in different stages of leukemogenesis remains incompletely understood.

Purpose of the Study:

  • To investigate the stage-specific functions of DNMT3A R882 mutations in human acute myeloid leukemia.
  • To determine the necessity of DNMT3A R882 mutations for maintaining leukemia stem cell properties.
  • To evaluate the therapeutic window for targeting DNMT3A-mutant clones.

Main Methods:

  • Utilized allele-specific CRISPR/Cas9 correction in human AML samples.
  • Dissected the functional impact of DNMT3A R882 mutations at preleukemic and established leukemia stages.
  • Assessed effects on cell self-renewal, inflammatory programs, and leukemia stem cell frequency.

Main Results:

  • DNMT3A R882 mutations are essential for sustaining self-renewal and inflammatory programs in preleukemic cells.
  • These mutations become largely dispensable for leukemia maintenance once the disease is established.
  • DNMT3A R882 mutations continue to influence leukemia stem cell frequency even in established leukemia.

Conclusions:

  • DNMT3A R882 mutations play a critical, stage-specific role in AML development, primarily during the preleukemic phase.
  • Targeting DNMT3A-mutant clones early in leukemogenesis may represent a viable therapeutic strategy.
  • These findings provide a preclinical rationale for reconsidering the timing of therapeutic interventions in DNMT3A-mutant AML.